Introduction {#s1}
============

Rates of chlamydia and gonorrhoea have risen in urban centres in Canada including an increase in case reports among men who have sex with men (MSM).[@R1] Coinfection with HIV is particularly concerning because sexually transmitted infections (STIs) can increase likelihood of HIV transmission.[@R1] In Ontario, Canada, we previously reported demographic and clinical risk factors for new chlamydia and gonorrhoea diagnoses among an HIV clinical cohort followed from 2008 to 2011.[@R2] Risk was highest among MSM, particularly among younger MSM and (for gonorrhoea) among MSM with unsuppressed viral load, with little variation between ethnic groups.[@R2] However, full characterisation of risk requires examination of behavioural risk factors since sexual behaviour and prevalence in sexual networks drive STI risk. 'Serosorting', selecting sexual partners of the same HIV serostatus, could raise STI risk since condoms may be used less frequently, which could concentrate infection in sexual networks of HIV-positive persons.[@R3] Recreational drug use has also been linked to sexual risk taking.[@R1] [@R4] [@R5] Our objective was to extend our previous analysis by longitudinally exploring behavioural risk factors for diagnoses of genital chlamydia and gonorrhoea infection among HIV-positive MSM attending HIV care in Ontario, specifically focusing on the risks associated with serosorting and recreational drug use.

Methods {#s2}
=======

We analysed data from the Ontario HIV Treatment Network Cohort Study (OCS) which follows persons attending 10 HIV clinics across Ontario. The province has publicly funded, universal access to medically necessary healthcare. The OCS has been described in detail elsewhere[@R6] and received ethical approval from the University of Toronto HIV Research Ethics Board (protocol reference 23954) and participating sites. Participation is voluntary. Data were collected through chart review, annual interviews and record linkage with the Public Health Ontario Laboratories (PHOL). At PHOL, simultaneous cotesting of chlamydia and gonorrhoea urine specimens was done by nucleic acid amplification testing using the Gen-Probe Aptima assay (Gen-Prose, San Diego, California, USA). Canadian guidelines recommend chlamydia and gonorrhoea testing annually for MSM at ongoing risk, regardless of HIV status.[@R1]

Our focus was on sexual behaviour and recreational drug use risk factors, adjusting for age, region and time-updated viral load as potential confounders. Men reported recreational drug use in face-to-face interviews. Next, they self-completed a computerised sexual behaviour questionnaire without interviewers present.

As of 12/2013, there were 6408 enrolees. Our analysis included 1997 male participants reporting non-heterosexual orientation or sex with men as an HIV risk factor; self-completed at least one sexual behaviour questionnaire between 2010 and 2013 and attended one of seven clinics that submitted all chlamydia and gonorrhoea tests to PHOL, the primary provider for chlamydia and gonorrhoea tests for sexual health clinics (HIV specialty and primary care clinics may also send specimens to private laboratories).

We conducted all statistical analyses using SAS V.9.3 (SAS Institute, Cary, North Carolina, USA). p Values were two-sided and statistical significance was determined using the p value of \<0.05. We used Kaplan--Meier methods to estimate the cumulative incidence proportions tested for or diagnosed with chlamydia or gonorrhoea following completion of the first sexual behaviour questionnaire. As previously done, diagnosis rates were calculated among tested and untested participants[@R2] thus underestimating true incidence since asymptomatic infections among those untested are excluded from the numerator.

For risk factor analysis, we grouped chlamydia and gonorrhoea into a composite outcome to improve statistical power and because their modes of transmission and clinical/public health implications are similar; HR estimates for separate chlamydia and gonorrhoea outcomes were not meaningfully different. For men diagnosed more than once, we selected the earliest event, which occurred rarely. We excluded participants with missing data (1.3% of observations) and two cases with zero event times. Men with no events were censored using the earliest of the dates of loss to follow-up, death or 31 December 2013.

Results {#s3}
=======

At completion of their first sexual behaviour questionnaire, men were aged 48 years, on average ([table 1](#SEXTRANS2015052500TB1){ref-type="table"}). The median number of years since HIV diagnosis was 18 (IQR 10--24). The majority (64.4%) were sexually active in the preceding 3 months, whereas a minority (20.9%) reported recreational drug use ([table 1](#SEXTRANS2015052500TB1){ref-type="table"}).

###### 

Characteristics of HIV-positive men who have sex with men (MSM) at completion of their first sexual behaviour questionnaire, OHTN Cohort Study, 2010--2013

  ----------------------------------------------------- -------------------
  Total N                                               1997 (100%)
  Mean age at baseline (SD)                             47.7 (10.2)
  Self-reported sexual orientation                      
   Gay                                                  1767 (88.5%)
   Bisexual                                             151 (7.6%)
   Heterosexual                                         58 (2.9%)
   Unknown\*                                            21 (1.1%)
  Race/ethnicity                                        
   White                                                1492 (74.7%)
   Black/African                                        80 (4.0%)
   Mixed race/ethnicity                                 168 (8.4%)
   Indigenous                                           85 (4.3%)
   Other                                                170 (8.5%)
  Education                                             
   High school or less                                  448 (22.4%)
   Some postsecondary                                   435 (21.8%)
   Completed postsecondary                              1111 (55.6%)
  Annual personal income                                
   \<\$C20 000                                          702 (35.2%)
   \$C20 000--\$C59 999                                 794 (39.8%)
   ≥\$C60 000                                           470 (23.5%)
   Unknown                                              31 (1.6%)
  Region where receiving HIV care                       
   Toronto                                              1703 (85.3%)
   Other                                                294 (14.7%)
  Year of HIV diagnosis                                 
   Prior to 2000                                        1129 (56.5%)
   2000--2009                                           737 (36.9%)
   2010 or later                                        131 (6.6%)
   Median (IQR)                                         1997 (1991--2005)
  HIV clinical status                                   
   Initiated antiretroviral treatment                   1647 (82.5%)
   Mean CD4 cell count/mm^3^ (SD)                       537 (253)
   Undetectable viral load (\<40 copies/mL)             1568 (78.5%)
  Recreational drug use in the preceding 6 months       
   Any†                                                 418 (20.9%)
   Methamphetamines                                     188 (9.4%)
   Cocaine                                              205 (10.3%)
   Club drugs‡                                          217 (10.9%)
   Other§                                               187 (9.4%)
   Multiple (two or more)                               232 (11.6%)
  *Sexual behaviours in the preceding 3 months*         
  Number of sexual partners                             
   None                                                 710 (35.6%)
   One                                                  535 (26.8%)
   Two to four                                          452 (22.6%)
   Five or more                                         274 (13.7%)
  Number of HIV-positive partners                       
   None                                                 1210 (60.6%)
   One                                                  330 (16.5%)
   Two to four                                          255 (12.8%)
   Five or more                                         100 (5.0%)
  Number of HIV-negative/status unknown partners        
   None                                                 1101 (55.1%)
   One                                                  364 (18.2%)
   Two to four                                          229 (11.5%)
   Five or more                                         214 (10.7%)
  Anal sex                                              
   No partner                                           710 (35.6%)
   Sexually active but no anal sex                      319 (16.0%)
   Anal sex always with a condom                        349 (17.5%)
   Any condomless anal sex                              551 (27.6%)
  Anal sex with HIV-positive partners¶                  
   No HIV-positive partners                             1210 (60.6%)
   Sexually active but no anal sex                      124 (6.2%)
   Anal sex always with a condom                        147 (7.4%)
   Any condomless anal sex                              416 (20.8%)
  Anal sex with HIV-negative/status unknown partners¶   
   No HIV-negative/status unknown partners              1101 (55.1%)
   Sexually active but no anal sex                      214 (10.7%)
   Anal sex always with a condom                        347 (17.4%)
   Any condomless anal sex                              257 (12.9%)
  ----------------------------------------------------- -------------------

\*Only 0.1% of the sample had missing data for race/ethnicity and 0.2% for education.

†Any recreational drug use includes anabolic steroids, amphetamines, methamphetamines, cocaine, crack/freebase, club drugs, heroin, other opiates, tranquilisers and other drugs, except cannabis as it was unmeasured for 4/7 participating clinic sites.

‡Club drugs include Ecstasy/MDMA (3,4-methylenedioxy-methamphetamine), Special K (ketamine), GHB (γ hydroxybutyrate), PCP (phencyclidine) and poppers (amyl nitrite).

§Other includes anabolic steroids, amphetamines, crack/freebase, heroin, other opiates, tranquilisers and 'other' option in drug use section of questionnaire.

¶Serostatus-specific variables were not mutually exclusive. The sexual behaviour questionnaire had a series of questions for HIV-positive partners followed by questions specific to HIV-negative/status unknown partners allowing for the capture and coding of different sexual practices by HIV status of partners.

Men were followed a median of 2.9 years (IQR 1.8--3.3) for a sum of 5833 person-years. The Kaplan--Meier cumulative probabilities of testing for chlamydia/gonorrhoea were 24.6% at 12 months and 33.1% at 24 months. In all, 35.1% (700/1997) were tested over the entire course of follow-up. The majority of tests were ordered by participating HIV clinics (87.6%) with only 3.0% ordered by sexual health/STI/community health clinics and 9.3% by other health providers. Stratum-specific 12-month testing probabilities ranged from 15.8% among sexually inactive men to 42.5% among men reporting 5+ partners ([table 2](#SEXTRANS2015052500TB2){ref-type="table"}).

###### 

Behavioural risk factors for a diagnosis of genital chlamydia/gonorrhoea infection at follow-up among HIV-positive MSM, OHTN Cohort Study, 2010--2013

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sexual behaviours in preceding 3 months\*                Cumulative probability of testing at 12 months (95% CI)†   Cumulative incidence of diagnosis at 12 months (95% CI)†   Unadjusted HR (95% CI)   Multivariable model A‡: adjusted HR\   Multivariable model B‡: adjusted HR (95% CI)
                                                                                                                                                                                                          (95% CI)                               
  -------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ------------------------ -------------------------------------- ----------------------------------------------
  Number of sexual partners                                                                                                                                                                                                                      

   None                                                    15.8 (13.3 to 18.4)                                        0.4 (0.0 to 0.8)                                           Reference                Reference                              

   One                                                     20.0 (16.7 to 23.3)                                        0.7 (0.0 to 1.4)                                           2.7 (0.9 to 7.9)                                                

   Two to four                                             33.9 (29.7 to 38.1)                                        3.0 (1.5 to 4.6)                                           10.3 (4.0 to 26.6)       3.1 (1.4 to 6.6)                       

   Five or more                                            42.5 (36.7 to 48.3)                                        4.8 (2.4 to 7.3)                                           16.0 (6.1 to 41.7)       3.7 (1.7 to 8.3)                       

  Number of HIV-positive partners                                                                                                                                                                                                                

   None                                                    19.0 (16.9 to 21.2)                                        0.8 (0.3 to 1.2)                                           Reference                                                       Reference

   One                                                     26.8 (22.2 to 31.4)                                        2.2 (0.7 to 3.8)                                           2.3 (1.1 to 4.7)                                                

   Two to four                                             40.1 (34.2 to 45.9)                                        2.9 (0.9 to 5.0)                                           5.0 (2.7 to 9.4)                                                1.6 (0.7 to 3.6)

   Five or more                                            42.3 (32.8 to 51.7)                                        8.3 (3.1 to 13.5)                                          13.5 (7.1 to 25.5)                                              3.3 (1.4 to 7.8)

  Number of HIV-negative/status UK partners                                                                                                                                                                                                      

   None                                                    20.9 (18.6 to 23.2)                                        1.1 (0.5 to 1.7)                                           Reference                                                       Reference

   One                                                     22.3 (18.2 to 26.4)                                        1.0 (0.0 to 2.0)                                           1.0 (0.5 to 2.0)                                                

   Two to four                                             34.6 (28.6 to 40.5)                                        2.5 (0.5 to 4.4)                                           2.2 (1.2 to 4.3)                                                1.2 (0.5 to 2.9)

   Five or more                                            33.7 (27.6 to 39.9)                                        4.8 (2.0 to 7.5)                                           3.5 (1.9 to 6.2)                                                1.2 (0.5 to 3.0)

  Anal sex                                                                                                                                                                                                                                       

   No partner                                              15.8 (13.3 to 18.4)                                        1.0 (0.3 to 1.7)                                           Reference                Reference                              

   Sexually active but no anal sex§                        20.8 (16.5 to 25.1)                                        1.3 (0.0 to 2.5)                                           1.9 (1.1 to 3.3)         0.5 (0.1 to 3.0)                       

   Anal sex always with a condom                           25.6 (21.2 to 30.0)                                        3.4 (1.5 to 5.3)                                           1.9 (0.5 to 6.9)         3.3 (1.0 to 11.4)                      

   Any condomless anal sex                                 36.8 (32.9, 40.7)                                          6.0 (4.1 to 8.0)                                           7.0 (2.5 to 19.0)        3.6 (1.0 to 12.3)                      

  Anal sex with HIV+ partner                                                                                                                                                                                                                     

   No HIV+ partner                                         19.0 (16.9 to 21.2)                                        0.8 (0.3 to 1.2)                                           Reference                                                       Reference

   Sexually active with HIV+ partner but no anal sex§      17.1 (10.7 to 23.5)                                        0.0 (0.0 to 0.0)                                           1.0 (0.2 to 4.4)                                                1.2 (0.3 to 5.2)

   Anal sex with HIV+ partner always with a condom         28.5 (21.5 to 35.4)                                        1.2 (0.0 to 2.8)                                           4.0 (1.8 to 8.8)                                                2.8 (0.6 to 13.4)

   Any condomless anal sex with HIV+ partner               40.6 (35.9 to 45.2)                                        5.4 (3.3 to 7.5)                                           6.3 (3.7 to 10.8)                                               2.2 (0.5 to 9.8)

  Anal sex with HIV−/UK partner                                                                                                                                                                                                                  

   No HIV−/UK partner                                      20.9 (18.6 to 23.2)                                        1.1 (0.5 to 1.7)                                           Reference                                                       Reference

   Sexually active with HIV−/UK partner but no anal sex§   22.3 (16.9 to 27.7)                                        0.4 (0.0 to 1.3)                                           0.7 (0.2 to 2.0)                                                1.6 (1.5 to 5.1)

   Anal sex with HIV−/UK partner always with a condom      29.6 (25.0 to 34.2)                                        2.8 (1.2 to 4.5)                                           2.0 (1.1 to 3.7)                                                2.2 (0.7 to 6.9)

   Any condomless anal sex with HIV−/UK partner            35.0 (29.3 to 40.7)                                        3.3 (1.2 to 5.5)                                           3.0 (1.6 to 5.3)                                                1.7 (0.6 to 5.3)

  Any recreational drug use in preceding 6 months¶                                                                                                                                                                                               

   No                                                      21.1 (19.2 to 23.0)                                        0.9 (0.4 to 1.3)                                           Reference                Reference                              Reference

   Yes                                                     38.2 (33.7 to 42.8)                                        4.7 (2.8 to 6.7)                                           5.0 (3.1 to 5.9)         1.8 (1.1 to 3.2)                       2.2 (1.2 to 3.9)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

UK=status unknown.

\*Behaviours were time-updated at each completion of a sexual behaviour questionnaire.

†Cumulative incidence proportions for testing and diagnosis were calculated using Kaplan--Meier methods.

‡Multivariable models adjusted for variables shown plus baseline age, region and time-updated viral load. Model A includes measures of sexual behaviours with HIV-negative, HIV-positive and HIV status unknown partners grouped together. Model B distinguishes sexual behaviour according to partners\' HIV status.

§The category 'sexually active, but no anal sex' was assigned to men who reported one or more partners to the question 'In the last 3 months how many male partners have you had sex with?' but responded 'Never' to the statements 'I had anal sex with him' for any reported HIV-positive or HIV-negative/status unknown partner.

¶Drug use was time -updated at each completion of a face-to-face interview. All drugs were combined to avoid multicollinearity.

MSM, men who have sex with men.

At follow-up, 41, 46 and 74 men were diagnosed with chlamydia, gonorrhoea and either pathogen, respectively. The Kaplan--Meier 12-month cumulative incidence proportions were 1.0% (95% CI 0.6% to 1.4%) for chlamydia, 1.2% (95% CI 0.7% to 1.7%) for gonorrhoea and 1.7% (95% CI 1.1% to 2.2%) for the composite outcome. Among cases, 53% (39 of 74) had a history of syphilis compared with 9.5% among non-cases.

Multiple sex partners and recreational drug use were significant risk factors for diagnosis ([table 2](#SEXTRANS2015052500TB2){ref-type="table"}). Risk was elevated among men who reported 5+ HIV-positive partners but not for multiple HIV-negative/unknown partners in the adjusted model. Recreational drug use doubled risk. Point estimates indicated elevated risk with anal sex (regardless of condom use); however, there was inadequate precision to indicate statistical significance.

Discussion {#s4}
==========

Among gay and other MSM in an Ontario HIV-positive clinical cohort from 2010 to 2013, the 12-month cumulative incidence of a genital chlamydia/gonorrhoea diagnosis was substantial at 1.7% (95% CI 1.1% to 2.2%). Risk factors were having multiple HIV-positive partners and recreational drug use. Strengths of our analysis include a large sample, tests from a single laboratory and 98% completion rate of the sexual behaviour questionnaire. To our knowledge, our study is the first to compare longitudinal chlamydia/gonorrhoea diagnosis rates from multiple clinics among HIV-positive MSM by partners\' HIV status.

There are limitations. Canadian and US guidelines recommend extragenital testing if engaging in oral or rectal intercourse[@R2] yet such tests were rarely done in our setting, meaning we could not identify rectal or pharyngeal infection risk factors. A 3-month time frame for sexual behaviours mitigated recall error but resulted in unmeasured behaviour between annual questionnaires, potentially explaining the non-zero diagnosis rate among men reporting no partners. Measurement of recreational drug use via face-to-face interviews may have introduced social desirability bias. Voluntary participation may have introduced selection bias. The OCS under-represents recent diagnoses; however, participants are generalisable to HIV-positive persons in Ontario according to sex, region, age at diagnosis and HIV exposure category.[@R7]

Recreational drug use was also a risk factor for chlamydia/gonorrhoea diagnosis in cross-sectional prevalence studies executed in clinics in Madrid and the Netherlands,[@R4] [@R5] which was demonstrated for genital, rectal and pharyngeal infections. The Netherlands study reported multiple partners as a risk factor for chlamydia, gonorrhoea and syphilis combined; however, the association became null when syphilis and chlamydia/gonorrhoea were analysed separately. The Madrid study reported risk associated with serosorting, defined as having a stable HIV-positive partner, whereas in our setting having multiple HIV-positive partners was most important.

Only 5% of men reported 5+ HIV-positive partners, but risk was highest in this group, with 12-month diagnosis rates of 8.3% (95% CI 3.1% to 13.5%). After adjustment for HIV-positive partners, no additional risk was associated with having multiple HIV-negative/unknown partners. We propose three hypotheses. First, men may use condoms less frequently for 'poz' sex; however, we observed similar risks between condom users and non-users. Second, HIV-positive men may choose receptive anal sex with HIV-negative partners reducing their risk of genital infection;[@R3] however, information on seropositioning was unavailable. Third, chlamydia/gonorrhoea may have achieved high prevalence in sexual networks among HIV-positive MSM seeking other positive men, and these networks may have low connectedness with HIV-negative MSM. That half of cases had a history of syphilis suggests presence of a core group where bacterial STIs are concentrated. In a study of German MSM, HIV-positive serosorters had threefold higher odds of bacterial STIs versus those with serodiscordant partners.[@R8] Together with our finding of heightened risk for recreational drug use, we recommend further investigation of how 'scene' participation (eg, poz parties, bathhouses) influences STI risk.[@R1] Further, as more HIV-negative men use pre-exposure prophylaxis for HIV prevention, sexual networks between HIV-negative and HIV-positive men may become more connected if serosorting becomes less common,[@R9] resulting in more population-level transmission of bacterial STI.

Our findings have implications for chlamydia/gonorrhoea prevention, testing and treatment among HIV-positive MSM. Non-zero diagnosis rates among men reporting condom-protected anal sex suggests some acquisition through unmeasured risk practices such as oral sex;[@R1] sexual education messages should emphasise the differences in bacterial STI transmission routes compared with HIV. Testing was below recommended guidelines; the proportion of untested men reporting high-risk behaviours was substantial. We strongly encourage rectal testing which could detect up to 80% more asymptomatic infections.[@R5] There is a need to design and deliver interventions to promote safer sex and testing in ways that are engaging, non-stigmatising and acceptable for men at risk. Potential clinic-based interventions to optimise testing include algorithms targeting high-risk patients, clinical decision support systems, automated patient/provider alerts and laboratory technologies to improve case detection.[@R10]
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